Intraosseous Spindle Cell Rhabdomyosarcoma with MEIS1::NCOA2 Fusion–Case Report with Substantial Clinical Follow-up and Review of the Literature

Benjamin F. Smith, Yee Cheen Doung, Brooke Beckett, Christopher L. Corless, Lara E. Davis, Jessica L. Davis

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Spindle cell/sclerosing rhabdomyosarcoma (SSRMS) is a clinicopathologically and molecularly heterogeneous disease. Gene fusions have been identified in intraosseous SSRMS, consisting predominantly of EWSR1/FUS::TFCP2 and MEIS1::NCOA2. The former often follow an aggressive clinical course; there is limited clinical follow-up available for the latter. We report here a new case of the very rare intraosseous SSRMS with MEIS1::NCOA2 gene fusion and include the detailed treatment course and 52 months of clinical follow-up. SSRMS with MEIS1::NCOA2 gene fusion appears biologically distinct from other intraosseous SSRMS, following a course characterized by local recurrence with rare reports of metastasis to date.

Original languageEnglish (US)
Pages (from-to)704-712
Number of pages9
JournalCancer Investigation
Volume41
Issue number8
DOIs
StatePublished - 2023

Keywords

  • MEIS1
  • NCOA2
  • Rhabdomyosarcoma
  • bone
  • gene fusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Intraosseous Spindle Cell Rhabdomyosarcoma with MEIS1::NCOA2 Fusion–Case Report with Substantial Clinical Follow-up and Review of the Literature'. Together they form a unique fingerprint.

Cite this